Cost effectiveness of omalizumab for severe asthma in Colombia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost effectiveness of omalizumab for severe asthma in Colombia

Published:2023-10-10 Issue: Volume: Page:1-8
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Buendía Jefferson Antonio¹²^ORCID,Guerrero Patiño Diana²,Zuluaga Salazar Andrés Felipe²³

Affiliation:

1. Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK

2. Research group in Pharmacology and Toxicology, Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia

3. Laboratorio Integrado de Medicina Especializada (LIME), Facultad de Medicina, IPS Universitaria, Universidad de Antioquia, Antioquia, Colombia

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2023.2267129

Reference25 articles.

1. Global asthma prevalence in adults: findings from the cross-sectional world health survey

2. Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma

3. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review

4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

5. Global Iniciative for Asthma Management and Prevention 2020. Available from: www.ginaasthma.org.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP